Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MIN-101 in Healthy CYP2D6 Extensive and Poor Metabolizers
NCT03072056Phase 1Completed
- Sponsor
- Minerva Neurosciences, Inc.
- Start
- Jan 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of roluperidone in schizophrenia (2 arms), sponsored by Minerva Neurosciences, Inc. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 4 more. Started Jan 2017; status: completed.
02
Drugs
roluperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03072056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03072056.